Previous 10 | Next 10 |
TECENTRIQ ® in Combination with ABRAXANE ® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination...
Activist investor Starboard Value, an opponent of Bristol-Myers Squibb's ( BMY -0.5% ) $74B takeout of Celgene ( CELG -0.1% ), is investigating whether hedge funds are using a controversial stock-trading tactic to sway the vote in favor of the deal, turning their long positions in Celg...
Bristol-Myers Squibb (NYSE: BMY ) met with sell-side analysts on Friday, March 8, as part of its campaign to sell the merits of its announced $74B bid for Celgene (NASDAQ: CELG ), a deal that lacks support from key shareholders. More news on: Bristol-Myers Squibb Company, Celgene Corporati...
New Drug Application submission to U.S. FDA on track for end of March Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-r...
In January 2019, Bristol-Myers Squibb ( BMY ) announced its intention to acquire and merge with Celgene ( CELG ) for $50 cash plus one share of BMY plus a CVR valued at $9/share which drove CELG's shares up to the $90+ mark. However, since that announcement, several major shareholders of B...
New York-based pharma giant Pfizer (NYSE: PFE) sold US$5bn of new corporate bonds Monday in five parts, as the company contributes to a groundswell of issuance amid low U.S. interest rates. The senior unsecured deal, comprised of maturities ranging from two- to 30-years, attracted decent dem...
Bristol-Myers Squibb (NYSE: BMY ) has sent an open letter to stockholders outlining the benefits of its planned acquisition of Celgene (NASDAQ: CELG ). Key points: More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Merger & acquisition news, ...
Who wants BMS? The proposition that there are acquirers who want to own Bristol-Myers Squibb ( BMY ) at a notably higher price than the current $52-53 trading range seems to be taken for granted. As Starboard Value LP said in a recent open letter to BMY shareholders: There is a better ...
U.S. Food & Drug Administration sets Prescription Drug User Fee Act action date for Sept. 3, 2019 Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a...
In this article, I will be covering a couple of lessons I learned from the Qualcomm ( QCOM )/NXP Semiconductor ( NXPI ) deal that can be applied to the latest mega-merger that is facing questions: Bristol-Myers Squibb ( BMY ) and Celgene ( CELG ). Lesson #1: Watch the spread From the begin...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...